Lisa Schrenk’s life changed after a hiking trip last August, when she overheard fellow hikers discussing hormone therapy. The federal IT specialist had spent months battling treatment-resistant depression and suicidal thoughts, but after switching to a telehealth provider, her symptoms improved dramatically.
The shift reflects a broader trend: demand for perimenopause-focused telehealth services has surged 490% since 2023, driven by the FDA’s 2025 removal of black-box warnings on hormone therapy and a cultural embrace of virtual care. Startups like Midi, Winona, Alloy, and Evernow now dominate a market targeting women in their 30s to 50s, with some charging up to $200 monthly for custom formulations.
Critics argue the industry’s expansive symptom lists—including fatigue, anxiety, and even wrinkles—risk overdiagnosis, as no lab test confirms perimenopause. Mayo Clinic’s Stephanie Faubion calls the hype "completely out of hand," while Yale’s Mary Jane Minkin urges caution but acknowledges the need for better awareness.
The debate centers on balancing access with oversight, as telehealth makes hormones easier to obtain but harder to regulate.
